Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant?

Front Pediatr · 2022 · PMC8987503 · PMID 35402356

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a randomized phase 3 COG/PBMTC trial, the addition of sirolimus, an mTOR inhibitor, to tacrolimus/methotrexate GVHD prophylaxis in children with ALL decreased grade 2–4 aGVHD but did not improve survival as the occurrence of grades 1–3 aGVHD showed a trend toward decreased relapse and improved EFS ( 37 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.